Moderna (MRNA) stock surged 177% on August 19 after the company and Merck announced positive Phase 3 results for an experimental personalized mRNA cancer therapy. Merck (MRK) climbed 12.6% as investorModerna (MRNA) stock surged 177% on August 19 after the company and Merck announced positive Phase 3 results for an experimental personalized mRNA cancer therapy. Merck (MRK) climbed 12.6% as investor
Why Is Moderna Stock Up 177%? MRNA and Merck Surge on Phase 3 Cancer Vaccine Results
Key Takeaways
Moderna surged after its Phase 3 melanoma study with Merck met key endpoints for recurrence-free survival and distant metastasis-free survival. The result strengthens the case for personalized mRNA cancer therapy, while detailed data and regulatory review remain the next major catalysts.
Moderna (MRNA) stock surged 177% on August 19 after the company and Merck announced positive Phase 3 results for an experimental personalized mRNA cancer therapy. Merck (MRK) climbed 12.6% as investors reassessed both the commercial opportunity for the treatment and the broader potential of combining mRNA technology with cancer immunotherapy.
The treatment, intismeran autogene, is being developed by Moderna in combination with Merck's Keytruda for patients with high-risk melanoma whose tumors have been surgically removed. In the Phase 3 INTerpath-001 trial, the combination met its primary endpoint of recurrence-free survival and a key secondary endpoint measuring whether cancer had spread to distant parts of the body.
For Moderna, that result carries significance far beyond one strong trading session. It provides the company's clearest late-stage evidence yet that its mRNA platform can produce important therapies outside infectious-disease vaccines.
What to Know
- Moderna stock surged 177% on August 19, while Merck gained 12.6%.
- The Phase 3 INTerpath-001 trial enrolled 1,137 patients with surgically removed Stage IIB–IV melanoma.
- Intismeran plus Keytruda met endpoints for recurrence-free survival and distant metastasis-free survival.
- Intismeran is personalized using mutations found in an individual patient's tumor.
- The therapy remains investigational and has not yet received commercial approval.
Why Did Moderna Stock Surge 177%?
Moderna's valuation has long depended on whether the company could turn mRNA from a highly successful COVID-era vaccine technology into a broader therapeutic platform. The latest melanoma result gives investors the strongest Phase 3 evidence so far that this transition may be possible.
The INTerpath-001 trial enrolled 1,137 patients with completely resected Stage IIB through Stage IV melanoma. Patients received either Keytruda plus intismeran or Keytruda alone. Moderna and Merck said the combination produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival, with no new safety signals identified.
The companies outlined the results in their official Phase 3 announcement, while Reuters reported that the successful trial marked a major validation for personalized mRNA cancer treatment.
The size of the stock reaction reflects how much uncertainty the result removed. Earlier-stage melanoma data had already been encouraging, but a failed Phase 3 trial would have significantly weakened expectations for Moderna's personalized cancer platform. A positive late-stage result instead moves the therapy closer to regulatory review and increases the relevance of similar studies underway in other cancers.
Short positioning likely amplified the move. Reuters reported that Moderna short sellers faced record one-day losses as the clinical result forced investors positioned for further weakness to reassess the stock rapidly.
The same announcement also explains the rise in Merck shares, but its impact on the two companies is not equal. Merck already owns a large, diversified pharmaceutical portfolio and Keytruda is an established oncology franchise. For Moderna, a successful cancer program has the potential to reshape expectations for the entire company. That helps explain why MRNA rose 177% while MRK gained 12.6%.
How Does the Moderna-Merck Cancer Vaccine Work?
Despite being widely called a “cancer vaccine,” intismeran is not a conventional vaccine designed to prevent cancer in healthy people.
It is an individualized neoantigen therapy created using the genetic characteristics of a specific patient's tumor. Cancer cells often contain mutations that produce abnormal proteins, known as neoantigens, which can potentially help the immune system distinguish those cells from normal tissue.
Moderna uses mRNA to encode selected neoantigens identified from an individual patient's tumor. The goal is to teach the immune system to recognize those tumor-specific targets.
Keytruda works through a different mechanism. Merck's drug blocks the PD-1 pathway, which tumors can use to suppress immune activity. Put simply, intismeran is designed to help the immune system recognize what to attack, while Keytruda helps remove one of the brakes that may prevent an effective immune response.
Moderna discusses the approach and its broader cancer program in its Phase 3 intismeran investor update.
The program also extends beyond melanoma. Moderna and Merck are testing intismeran with Keytruda across several other tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Merck previously said the partners had nine Phase 2 and Phase 3 studies underway across multiple cancers.
That is why investors are looking beyond one melanoma indication. If the personalized mRNA approach works across multiple cancers, intismeran could eventually be valued as the foundation of a broader oncology platform rather than a single product.
What the Phase 3 Result Still Does Not Tell Investors
The headline result is important, but several major questions remain unresolved.
Moderna and Merck have not yet released the complete efficacy dataset. Investors still need the detailed recurrence-free survival and distant metastasis-free survival results, subgroup analyses and longer-term follow-up. Overall survival data are also not yet available. The companies plan to present fuller findings at a future medical meeting.
The treatment is also not yet approved. Moderna and Merck are discussing the results with regulators, but successful Phase 3 data still need to move through regulatory review before intismeran can become a commercial product.
Manufacturing adds another layer of uncertainty because every treatment is individualized. Producing a therapy based on the mutations found in one patient's tumor is fundamentally more complex than manufacturing millions of identical doses of a standardized medicine. Turnaround time, production capacity, consistency and cost could therefore become important parts of the commercial story.
Expectations are already rising quickly. Analysts cited by Reuters have estimated that melanoma-related sales could eventually reach around $3 billion annually by 2035, but those forecasts still depend on regulatory approval, adoption, pricing and manufacturing execution.
That creates an unusual setup for Moderna stock. The Phase 3 result materially strengthens the company's oncology thesis, but the market also repriced that opportunity extraordinarily quickly in a single session. The next phase will depend less on the initial headline and more on the detailed clinical data, regulatory path and whether similar results can be reproduced in additional cancers.
Eligible users interested in U.S. equities can review how MEXC RealStocks works or explore U.S. stocks and stock-related markets on MEXC, subject to regional availability and account eligibility.
FAQ
Why is Moderna stock up?
Moderna stock surged 177% after the Phase 3 INTerpath-001 trial with Merck met key recurrence-free survival and distant metastasis-free survival endpoints in high-risk melanoma. The result provides major late-stage validation for Moderna's personalized mRNA cancer platform.
Is Moderna's cancer vaccine approved?
No. Intismeran remains investigational. Moderna and Merck are discussing the Phase 3 results with regulators, but the personalized cancer therapy has not yet received commercial approval.
Market Opportunity
Notcoin Price(NOT)
--
----
USD
Notcoin (NOT) Live Price Chart
Description:Crypto Pulse is powered by AI and public sources to bring you the hottest token trends instantly. For expert insights and in-depth analysis, visit MEXC Learn.
The articles shared on this page are sourced from public platforms and are provided for reference only. They do not represent the position or views of MEXC. All rights belong to James Mitchell. If you believe any content infringes upon the rights of a third party, please contact service@support.mexc.com for prompt removal. MEXC does not guarantee the accuracy, completeness, or timeliness of any content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be interpreted as a recommendation or endorsement by MEXC. For expert insights and in-depth analysis, visit MEXC Learn.
Learn More About Notcoin
View More
Looking for MEXC Alternatives? Three Reasons to Switch, and 336 Reasons to Stay
Within this comparison, MEXC is our top pick for traders who buy new listings early and trade often, because 336 perpetual pairs and more than 600 spot pairs carry a zero-fee tag and the standard
2026/08/20
How to Hedge With Prediction Markets Before the Next Fed Decision Hits Your Portfolio
To hedge with prediction markets, you buy YES or NO event contracts that pay out one dollar per share when the outcome you fear occurs. The payout offsets the loss that the event inflicts on your
2026/08/20
Best Crypto Swap Exchange 2026: 8 Platforms Priced on the Same $500 Swap
For anyone comparing crypto swap services in 2026, MEXC is our top pick in this comparison: its Convert tool charges zero fees on a fixed quoted rate, its spot market adds a 0% maker fee across
2026/08/20
Latest Updates on Notcoin
View More
Stablecoins as Cash Equivalents: What FASB Proposes
The Financial Accounting Standards Board has proposed guidance explaining when certain stablecoins may qualify as cash equivalents under U.S. generally accepted accounting principles. The proposal reported on August 19 does not automatically classify every dollar-pegged token as cash. Instead, it would add illustrative examples to Topic 230, Statement of Cash Flows, showing how the existing definition of a cash equivalent may apply to digital assets with specific economic and legal characteristics
2026/08/19
Grayscale Zcash Trust Seeks NYSE Arca Listing
Grayscale Investments has advanced its effort to move the Grayscale Zcash Trust toward an exchange-listed structure, filing Amendment No. 4 to its Form S-3 registration statement on August 18, 2026. The filing states that the trust intends to list its shares on NYSE Arca under the ticker ZCSH. That language is important: the proposed listing should not be described as already approved by the U.S. Securities and Exchange Commission
2026/08/20
SEC’s Regulation Crypto Assets Proposal Reframes U.S. Token Fundraising
The SEC’s Regulation Crypto Assets proposal creates tailored token-sale exemptions and a safe harbor, but it is not yet final U.S. law.
2026/08/20
HOT
Currently trending cryptocurrencies that are gaining significant market attention
Crypto Prices
The cryptocurrencies with the highest trading volume
Newly Added
Recently listed cryptocurrencies that are available for trading